BEONE MEDICINES

Forecast & Rating16 analysts currently cover BEONE MEDICINES, with about 93.8% giving a positive rating — meaning they expect the stock to rise. The average price target is HK$278.48, about 3.1% upside from the current price of HK$270.00. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 66.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study BEONE MEDICINES closely still see room for the stock to rise. Data as of Nov 11, 2026; for reference only and not investment advice.